Published
2026-03-03
Issue
Section
Pharmacy Practice & Practice-Based Research
Categories
License
Copyright (c) 2026 Ronald G. Hall 2nd, Amie T. Blaszczyk, Hui Yang, Carlos A. Alvarez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
Impact of the 2008 US FDA warnings for fluoroquinolone use in veterans ≥ 60 years of age with lung cancer
Ronald G. Hall 2nd
Texas Tech University Health Sciences Center
https://orcid.org/0000-0002-5616-8246
Amie T. Blaszczyk
Texas Tech University Health Sciences Center
https://orcid.org/0000-0001-9530-3706
Hui Yang
Texas Tech University Health Sciences Center
Carlos A. Alvarez
Texas Tech University Health Sciences Center
https://orcid.org/0000-0002-9512-1870
DOI: https://doi.org/10.24926/iip.v16i4.6996
Keywords: fluoroquinolones, lung neoplasms, veteran, United States Food and Drug Administration, Interrupted Time Series Analysis
Abstract
Objectives: To evaluate the impact of the United States Food and Drug Administration's 2008 warnings on the use of fluoroquinolones in patients with lung cancer.
Methods: The impact of the 2008 FDA warnings on fluoroquinolone use in patients with lung cancer ≥ 60 years old in the VA system (2002-2022) was evaluated. Patients ≥ 60 years of age with lung cancer from January 1, 2002 to December 31, 2022, were included. The number of patients with a fluoroquinolone prescription or inpatient order for each calendar year was standardized as a percentage of newly diagnosed patients. Patients receiving a fluoroquinolone were also evaluated for the concomitant use of corticosteroids and QTc-prolonging medications, which were also standardized as a percentage of newly diagnosed patients. Interrupted time series analyses were used to evaluate the impact of the FDA warnings issued in 2008. The pre-period was 2002-2007, and the post-period was 2009-2022.
Results: Statistically significant reductions were observed in fluoroquinolone use for patients with lung cancer aged ≥ 60 years as well as the use of concomitant QTc-prolonging agents. Numerical reductions in the concomitant use of fluoroquinolones and corticosteroids were not statistically significant.
Conclusions: The use of fluoroquinolones and concomitant medications associated with safety risks has decreased over time. Healthcare providers caring for veterans with lung cancers have been responsive to the 2008 FDA warnings.
